#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Paramyxovirus Entry and Targeted Vectors for Cancer Therapy


article has not abstract


Vyšlo v časopise: Paramyxovirus Entry and Targeted Vectors for Cancer Therapy. PLoS Pathog 6(6): e32767. doi:10.1371/journal.ppat.1000973
Kategorie: Pearls
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1000973

Souhrn

article has not abstract


Zdroje

1. KellyE

RussellSJ

2007 History of oncolytic viruses: genesis to genetic engineering. Mol Ther 15 651 659

2. LiuTC

GalanisE

KirnD

2007 Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol 4 101 117

3. CattaneoR

MiestT

ShashkovaEV

BarryMA

2008 Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol 6 529 540

4. GalanisE

HartmannLC

ClibyWA

LongHJ

PeethambaramPP

2010 Phase I trial of intraperitoneal administration of an engineered strain of measles virus modified to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res 70 875 882

5. WaehlerR

RussellSJ

CurielDT

2007 Engineering targeted viral vectors for gene therapy. Nat Rev Genetic 8 573 587

6. NavaratnarajahCK

LeonardVHJ

CattaneoR

2009 Measles virus glycoprotein complex assembly, receptor attachment and cell entry. Curr Top Microbiol Immunol 329 59 76

7. SchneiderU

BulloughF

VongpunsawadS

RussellSJ

CattaneoR

2000 Recombinant measles viruses efficiently entering cells through targeted receptors. J Virol 74 9928 9936

8. BucheitAD

KumarS

GroteD

LinY

von MesslingV

2003 An oncolytic measles virus engineered to enter cells through the CD20 antigen. Mol Ther 7 62 72

9. VongpunsawadS

OezgunN

BraunW

CattaneoR

2004 Selectively receptor-blind measles viruses: identification of residues necessary for SLAM- or CD46-induced fusion and their localization on a new hemagglutinin structural model. J Virol 78 302 313

10. NakamuraT

PengKW

HarveyM

GreinerS

LorimerIA

2005 Rescue and propagation of fully retargeted oncolytic measles viruses. Nat Biotechnol 23 209 214

11. KinohH

InoueM

WashizawaK

YamamotoT

FujikawaS

2004 Generation of a recombinant Sendai virus that is selectively activated and lyses human tumor cells expressing matrix metalloproteinases. Gene Ther 11 1137 1145

12. SpringfeldC

von MesslingV

FrenzkeM

UngerechtsG

BuchholzCJ

CattaneoR

2006 Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases. Cancer Res 66 7694 7700

13. EgebladM

WerbZ

2002 New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2 161 174

14. KinohH

InoueM

KomaruA

UedaY

HasegawaM

YonemitsuY

2008 Generation of optimized and urokinase-targeted oncolytic Sendai virus vectors applicable for various human malignancies. Gene Ther 16 392 403

15. FunkeS

MaisnerA

MuehlebachMD

KoehlU

GrezM

2008 Targeted cell entry of lentiviral vectors. Mol Ther 16 1427 1436

16. BaumC

2008 On target: new envelopes for lentiviral vectors. Mol Ther 16 1349 1350

17. SpringfeldC

von MesslingV

TidonaCA

DaraiG

CattaneoR

2005 Envelope targeting: hemagglutinin attachment specificity rather than fusion protein cleavage-activation restricts Tupaia paramyxovirus tropism. J Virol 79 10155 10163

18. Ottolino-PerryK

DialloJ-S

LichtyBD

BellJC

McCartJA

2010 Intelligent design: combination therapy with oncolytic viruses. Mol Ther 18 251 263

19. UngerechtsG

SpringfeldC

FrenzkeME

LampeJ

JohnstonPB

2007 Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine. Cancer Res 67 10939 10947

20. UngerechtsG

FrenzkeME

YaiwK-C

MiestT

JohnstonPB

2010 Mantle cell lymphoma salvage regimen: synergy between a reprogrammed oncolytic virus and two chemotherapeutics. Gene Ther 18 In press

21. DingliD

PengKW

HarveyME

GreippPR

O'ConnorMK

2004 Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 103 1641 1646

22. GarberK

2006 China approves world's first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst 98 298 300

23. BellJ

2010 Oncolytic viruses: an approved product on the horizon? Mol Ther 18 233 234

24. HashiguchiT

KajikawaM

MaitaN

TakedaM

KurokiK

2007 Crystal structure of measles virus hemagglutinin provides insight into effective vaccines. Proc Natl Acad Sci U S A 104 19535 19540

25. YinH-S

WenX

PatersonRG

LambRA

JardetzkyTS

2006 Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformation. Nature 439 38 44

Štítky
Hygiena a epidemiológia Infekčné lekárstvo Laboratórium

Článok vyšiel v časopise

PLOS Pathogens


2010 Číslo 6
Najčítanejšie tento týždeň
Najčítanejšie v tomto čísle
Kurzy

Zvýšte si kvalifikáciu online z pohodlia domova

Získaná hemofilie - Povědomí o nemoci a její diagnostika
nový kurz

Eozinofilní granulomatóza s polyangiitidou
Autori: doc. MUDr. Martina Doubková, Ph.D.

Všetky kurzy
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa

#ADS_BOTTOM_SCRIPTS#